Table 1.

Ongoing clinical trials adopting tregs in autoimmunity.

Study ID	Phase	Indication	Enrollment/Age	Product	Dose	Status
ISRCTN06128462	I	Type 1 Diabetes	12/ range 5–18	Polyclonally expanded tTregs (A)	10 and 30 × 106/kg	Completed
NCT02691247	II	Type 1 Diabetes	113/ range 8–17	Polyclonally expanded tTregs (A)	2.5 and 20 × 106/kg	Active, not recruiting
NCT02772679	I	Type 1 Diabetes	16/ range 18–45	Polyclonally expanded tTregs (A)	3 and 20 × 106/kg	Recruiting
NCT02428309	I	Cutaneous Lupus	NA/ range 18–60	Polyclonally expanded tTregs (A)	1, 4 and 16 × 108	Active, not recruiting
NCT03239470	I	Pemphigus	12/ range 18–75	Polyclonally expanded tTregs (A)	2.5 × 108 and 10 × 108	Recruiting
NCT03011021	I/II	Type 1 Diabetes	40/ >18	Polyclonally expanded tTregs (UCB)	2 × 106/kg	Recruiting
NCT02932826	I/II	Type 1 Diabetes	40/ range 6–60	Polyclonally expanded tTregs (UCB)	2 × 106/kg	Recruiting
NCT02704338	I/II	Autoimmune hepatitis	30/ range 10–70	Polyclonally expanded tTregs (A)	10–20 × 106/kg	Unknown
NCT03185000	I/II	Crohn's Disease	20/ range 18–80	Polyclonally expanded naive tTregs (A)	0.5–1, 3–5 and 8–10 × 106/kg	Not yet recruiting

(A), autologous; (UCB), umbilical cord blood.